Abstract
Wilson’s disease (WD), also called hepatolenticular degeneration, is an autosomal recessive inheritance disorder of copper metabolism characterized by the multiple mutations in the ATP-ase 7B gene of chromosome 13q. About half of the WD patients have neurological or psychiatric symptoms. As WD is a kind of medicable or nearly curable neurodegenerative disease in the field of medicine, early consideration/examination and without delay/ life-long treatment usually lead to better prognoses. The drugs, also named as anticopper agents, are commonly used in clinics including D-penicillamine, trientine, sodium dimercaptosuccinate, dimercaptosuccinic acid, zinc and tetrathiomolybdate. This provides detailed reviews about these medicines.
Keywords: D-penicillamine, dimercaptosuccinic acid, hepatolenticular degeneration, sodium dimercaptosuccinate, tetrathiomolybdate, trientine, Wilson’s disease, zinc.
Graphical Abstract
Current Neuropharmacology
Title:Current Drug Managements of Wilson’s Disease: From West to East
Volume: 14 Issue: 4
Author(s): Wen-Jie Li, Chen Chen, Zhi-Fei You, Ren-Min Yang and Xiao-Ping Wang
Affiliation:
Keywords: D-penicillamine, dimercaptosuccinic acid, hepatolenticular degeneration, sodium dimercaptosuccinate, tetrathiomolybdate, trientine, Wilson’s disease, zinc.
Abstract: Wilson’s disease (WD), also called hepatolenticular degeneration, is an autosomal recessive inheritance disorder of copper metabolism characterized by the multiple mutations in the ATP-ase 7B gene of chromosome 13q. About half of the WD patients have neurological or psychiatric symptoms. As WD is a kind of medicable or nearly curable neurodegenerative disease in the field of medicine, early consideration/examination and without delay/ life-long treatment usually lead to better prognoses. The drugs, also named as anticopper agents, are commonly used in clinics including D-penicillamine, trientine, sodium dimercaptosuccinate, dimercaptosuccinic acid, zinc and tetrathiomolybdate. This provides detailed reviews about these medicines.
Export Options
About this article
Cite this article as:
Li Wen-Jie, Chen Chen, You Zhi-Fei, Yang Ren-Min and Wang Xiao-Ping, Current Drug Managements of Wilson’s Disease: From West to East, Current Neuropharmacology 2016; 14 (4) . https://dx.doi.org/10.2174/1570159X14666151130222427
DOI https://dx.doi.org/10.2174/1570159X14666151130222427 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Editorial (Thematic Selection: Strategies of Current Drugs and Alternative Treatments for Neurodegenerative Diseases)
Current Neuropharmacology Anti-Copper Therapies in Alzheimers Disease: New Concepts
Recent Patents on CNS Drug Discovery (Discontinued) Aceruloplasminemia
Current Drug Targets Re-Wiring the Circuit: Mitochondria as a Pharmacological Target in Liver Disease
Current Medicinal Chemistry